JP2015517458A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517458A5
JP2015517458A5 JP2015509430A JP2015509430A JP2015517458A5 JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5 JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5
Authority
JP
Japan
Prior art keywords
insulin
combination
des
human insulin
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015509430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517458A (ja
JP6262206B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/059073 external-priority patent/WO2013164375A1/en
Publication of JP2015517458A publication Critical patent/JP2015517458A/ja
Publication of JP2015517458A5 publication Critical patent/JP2015517458A5/ja
Application granted granted Critical
Publication of JP6262206B2 publication Critical patent/JP6262206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015509430A 2012-05-01 2013-05-01 医薬組成物 Active JP6262206B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12166252 2012-05-01
EP12166251.4 2012-05-01
EP12166251 2012-05-01
EP12166252.2 2012-05-01
US201261641540P 2012-05-02 2012-05-02
US201261641544P 2012-05-02 2012-05-02
US61/641,540 2012-05-02
US61/641,544 2012-05-02
PCT/EP2013/059073 WO2013164375A1 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2015517458A JP2015517458A (ja) 2015-06-22
JP2015517458A5 true JP2015517458A5 (enExample) 2016-06-16
JP6262206B2 JP6262206B2 (ja) 2018-01-17

Family

ID=49514218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509430A Active JP6262206B2 (ja) 2012-05-01 2013-05-01 医薬組成物

Country Status (9)

Country Link
US (1) US9884094B2 (enExample)
EP (1) EP2844274B1 (enExample)
JP (1) JP6262206B2 (enExample)
AU (1) AU2013255880B2 (enExample)
BR (1) BR112014026442A8 (enExample)
CA (1) CA2872083A1 (enExample)
MX (1) MX363119B (enExample)
RU (1) RU2670106C2 (enExample)
WO (1) WO2013164375A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
RU2495131C2 (ru) * 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
PL2632478T3 (pl) * 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu

Similar Documents

Publication Publication Date Title
JP2015517458A5 (enExample)
JP5669395B2 (ja) 新規化合物および摂食行動に対するその効果
RU2014147674A (ru) Фармацевтическая композиция
JP2016516076A5 (enExample)
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
EP2729493A1 (en) Novel compounds and their effects on feeding behaviour
JP2008534622A5 (enExample)
JP2017537894A (ja) Glp−1rおよびglp−2r二重アゴニスト活性を有する組成物及びペプチド
RU2013133803A (ru) Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
CA2608311A1 (en) Glp-1 pegylated compounds
JP2010031018A5 (enExample)
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
RU2006144821A (ru) Пролонгирующие метки полипептидов, содержащие тетразольную группировку
JP2015110631A5 (enExample)
CN102711805A (zh) 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
JP2011503152A5 (enExample)
JP2011001381A (ja) Glp−1医薬組成物
WO2014009316A1 (en) Novel use of insulin derivatives
EP1888103B1 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
JP2024038042A (ja) 肥満の治療および体重管理のためのglp-1組成物
JP2014500244A5 (enExample)
CN101378775A (zh) 对人促生长素抑制素受体亚型具有不同选择性的促生长素抑制素类似物的组合
Verge et al. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes
JP2013511287A5 (enExample)
Mikhail Is exenatide a useful addition to diabetes therapy?